Qiagen joins CANCER-ID consortium to promote standardised research models

Qiagen has become a member of the public-private consortium CANCER-ID, a partnership dedicated to promoting greater standardisation of liquid biopsy workflows.

The consortium consists of 36 partners from 13 countries and is part of Europe's Innovative Medicines Initiative. It is dedicated to establishing standard protocols and clinical validation for blood-based biomarkers in lung and breast cancer.

To achieve this goal, the partners conduct clinical trials using liquid biopsy methods to accelerate the development of better and safer medicines for patients. Qiagen will lend its experience in developing liquid biopsy sample technologies to aid this goal.

Markus Sprenger-Haussels, senior director and head of sample technologies for Qiagen's life sciences business, said: "Qiagen is pleased to be joining CANCER-ID to help develop standards and conduct clinical validation to enable broad adoption of reliable molecular analyses from liquid biopsies."

Liquid biopsies hold considerable promise across a range of clinical applications, including disease screening in patients for whom surgical biopsy is inappropriate, or in repeated testing to monitor changes in disease status.

However, protocols for the implementation of this method are currently extremely varied, as the process of collecting blood-based biomarkers has not yet been standardised.

With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.